Quantcast

New Clinical Data On Cellvizio to Be Presented At the 16th Annual United European Gastroenterology Week 2008

October 14, 2008

PARIS, Oct. 14, 2008 (GLOBE NEWSWIRE) — Mauna Kea Technologies, a leader in in vivo cellular imaging, announced today that four poster abstracts and one oral presentation regarding the company’s flagship technology, Cellvizio(r), will be presented at the 16th Annual 2008 United European Gastroenterology Week (UEGW) conference taking place in Vienna, Austria, October 18-22nd. Cellvizio, the world’s smallest microscope, is the first microscopic imaging system designed to provide live, extremely detailed images of internal human tissues during regular endoscopic procedures.

“We are pleased to have a significant presence at this year’s 16th Annual UEGW, a platform where leaders in gastro-intestinal endoscopy research gather,” Sacha Loiseau, Ph.D., president and CEO of Mauna Kea Technologies, noted. “These studies add to the growing clinical evidence validating Cellvizio’s ability to change how physicians diagnose and treat GI diseases such as Barrett’s esophagus and ulcerative colitis and pathologies in the bile and pancreatic ducts. By offering physicians a real-time microscopic look at internal tissues, Cellvizio allows them to make immediate informed decisions about how to properly treat a patient without days or weeks of waiting required for a lab to analyze biopsy samples and without having to bring the patient back for repeat procedures.”

Following are presentation details:

   Poster: Confocal laserscanning fluorescence microscopy for in-vivo  determination of micro-vessel density in Barrett's esophagus  Abstract Number: P0018  Lead Investigator: Valentin Becker, II Medical Department, Klinikum  rechts der Isar, Munich  Date: Monday, October 20, 2008  Time: 12:15 p.m. - 1:01 p.m.  Location: Austria Center Vienna; Vienna, Austria; Hall Z   Poster: Miniprobe confocal laser microscopy for the detection of  invisible neoplasia in patients with Barrett's esophagus  Abstract Number: P0027  Lead investigator: Valentin Becker, II Medical Department, Klinikum  rechts der Isar, Munich  Date: Monday, October 20, 2008  Time: 12:15 p.m. - 1:01 p.m.  Location: Austria Center Vienna; Vienna, Austria; Hall Z   Poster: Miniprobe-based confocal fluorescence microscopy is feasible  for in-vivo histological differentiation of neoplasia and  non-neoplastic tissue in patients with ulcerative colitis  Abstract Number: P0193  Lead investigator: J.A. van Es, Gastroenterology and Hepatology  Date: Monday, October 20, 2008  Time: 12:15 p.m. - 1:01 p.m.  Location: Austria Center Vienna; Vienna, Austria; Hall Z   Poster: Accuracy and interobserver agreement of international  experts on a new classification scheme for probe-based confocal  fluorescence microscopy  Abstract Number: P0484  Lead investigator: F.J.C. van den Broek, Gastroenterology, Academic  Medical Center, Amsterdam  Date: October 20, 2008  Time: 12:15 p.m. - 1:45 p.m.  Location: Austria Center Vienna; Vienna, Austria; Hall Z   Oral Presentation: Results of a phase I study on intraductal  confocal microscopy (idcm) in patients with common bile duct (cbd)  stenosis  Abstract Number: OP408  Lead investigator: Marc Giovannini, Endoscopic Unite, Paoli-Calmettes  Institute, Marseille, France  Date: October 22, 2008  Time: 11:00 a.m. - 12:12 p.m.  Location: Austria Center Vienna; Vienna, Austria; Hall Z 

About Mauna Kea Technologies and Cellvizio:

Manua Kea Technologies, which has changed its operating name to Cellvizio in the U.S., is a venture-backed medical device company based in Paris, France, with U.S. offices in Fort Washington, Penn. Investors include Psilos Group, Seventure and Creadev. The company leads the growing in vivo cellular imaging market enabling physicians to visualize, diagnose and treat pathologies that cannot be seen using other imaging techniques. Mauna Kea Technologies’ flagship Cellvizio(r) system provides microscopic visualization of mucosal tissue and promises to improve clinical outcomes by increasing the diagnostic yield of existing endoscopic procedures. With over 1,700 Cellvizio procedures completed to date, Mauna Kea Technologies is currently focused on the gastroenterology and pulmonology markets. The company plans to expand into other markets in the future. The company also has a distribution agreement with Leica Microsystems to sell products for the Small Animal Imaging market in Europe, the U.S. and Japan. For more information about Mauna Kea Technologies: www.maunakeatech.com

This news release was distributed by GlobeNewswire, www.globenewswire.com

 CONTACT:  Lazar Partners           Media Contacts:           Erich Sandoval           917-497-2867           esanodval@lazarpartners.com 



comments powered by Disqus